Sitemap
- Type 2 Diabetes Patients Weary of Byetta
- Pancreatic Cancer Patients Find Promising Treatment That Diminishes Tumor Size
- New Study Says Exercise Will Cut Type 2 Diabetes Risk
- Status of Patients Suffering From Dementia May Vary Based on Diabetes Diagnosis
- Combination of Therapies May Successfully Treat Pancreatic Cancer
- Biomarkers May Identify Early Stages of Pancreatic Cancer
- Treating Type 2 Diabetes
- Individuals Diagnosed With Diabetes Prior to Developing Cancer May Be at Increased Risk For Fatality
- New diabetes drug class effective, caution urged
- Analysis: Newest diabetes drugs pass test
- Do Newest Diabetes Drugs Work?
- 2 new diabetes drugs work, but need study
- Diabetes research seeks ally
- Biotech Firms Fear Innovation at Risk if Speedier Approval of Biologic ...
- BYETTA(R) Study Showed Comparable Blood Glucose Control to Insulin
- Novo Nordisk Upbeat on New Drug
- On Avandia, a Niche Strategy Now Under Stress
- Glaxo's African-American Strategy For Avandia May Backfire
- Market Report -- Story Stocks (GSK)
- GlaxoSmithKline defends Avandia as shares drop 13% in nine days
- More Questions Than Answers
- Diabetes drug warning could turn into boon for Lilly
- What Diabetes Patients Need to Know
- Avandia: Getting the Facts
- Surge expected for diabetes drug market
- Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
- Start Making $67,000 Today
- Zacks Analyst Interview Highlights: Xoma, Ltd., Merck & Co. and Amylin ...
- Nastech Nose Potential
- Analysis: Street split on Nastech
- San Diego Business Journal
- Amylin Expands Ohio Plant; Reportedly Offered $117M Incentive
- Amylin Expands Ohio Plant; Reportedly Offered $117M Incentive
- Amylin Pharmaceuticals to Present at Morgan Stanley
- Eli Lilly rolls out diabetes drug Byetta in Europe
- Ask Dr. H | Treating polycystic ovarian syndrome
- Less Meter is More
- Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and ...
- Lilly Reports Strong First-Quarter Results Raises Full-Year Sales...
- Keep Off the Weight
- Diabetes Treatment Helps With Weight Loss
- The Latest Class for Diabetes
- Merck up on FDA Janumet OK
- Market Report -- Story Stocks (MRK)
- Ask Dr. H | Treating polycystic ovarian syndrome
- Strickland touts investment
- Pharmaceutical firm plans big investment in region
- New biz already looking to grow
- Online Press Release
- Nurses oppose governor's plan
- More Related Stories
- Amylin Pharmaceuticals to Present at Cowen and Company Annual
- Midday Leaders & Laggards: Nasdaq 100
- A triumphant exit
- WHEN IS MEDICATION TO MUCH MEDICATION? HOW DO WE KNOW WHEN WE ARE OVER ...
- Novartis: FDA wants new Galvus study
- Market Report -- Story Stocks (NVS)
- Novartis: FDA wants new Galvus study
- New Storage Instructions Approved For BYETTA®
- Analysts split on Amylin
- Get FIT update
- Get FIT update
- Biopharma Giant Set to Rule Insulin Market
- Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development ...
- Forbes Medi-Tech Announces Next Steps in Pharmaceutical
- Biotech Starts Out on Right Foot in January
- Stocks to Watch, Jan. 31: Google, SanDisk and Allstate
- About-face: Lilly pulls plug on insulin plant
- Sector Preview: Biotechnology
- Schaeffer's Daily Market Blog Features: Walt Disney, Amazon.com, Telik ...
- Sector Preview: Biotechnology
- Education is the best medicine
- Diabetes Treatment Helps With Weight Loss
- Molecule could hold the key to diabetes` pill: Study
- Latest News
- Danish shares close higher, led up by Vestas, AP Moeller, Colopast ...
- Schaeffer's Daily Market Blog Features: Walt Disney, Amazon.com,
- Analysts See More Biotech M&A in 2007
- MARKET SNAPSHOT: U.S. Stocks Open Higher As Holiday Ends
- Telik's experimental cancer drug fails trials
- Futures edge up, oil may help energy shares
- Stocks to Watch, Dec. 25: Amylin, Openwave and UTStarcom
- Amylin's Byetta OK's for Expanded Use
- At the Helm:
- Amylin,Eli Lilly:FDA OKs BYETTA As Add-On Diabetes Therapy
- Amylin Pharmaceuticals (AMLN) and Eli Lilly (LLY) Announces FDA ...
- FDA Approves BYETTA(R) (exenatide) Injection for Expanded
- Nastech Obesity Drug Passes Dose-Ranging
- Nastech Shares Jump on Analyst Note
- Nastech Shares Jump on Analyst Note
- Shares dip on Eli Lilly earnings forecast
- Related Blog Posts & Articles
- Eli Lilly, Amylin Get EU OK for Byetta and ViroPharma to Present at ...
- Amylin Gets Past the Formalities
- Data show strong launch of new Merck diabetes drug
- submit a feature
- UPDATE 3-Novo Nordisk maintains 2006 forecasts, shares fall
- Forbes Medi-Tech to Acquire San Diego Based TheraPei Pharmaceuticals ...
- 'Today': Using an 'off-label' Rx to slim? Think twice
- Kiss of the Gila monster
- Eli Lilly third-quarter profit rises 10 percent
- Amylin's One-Drug Wonder
- Pfizer, Novartis, Wyeth post Q3 gains
- Earnings: Pfizer, McDonald's, Coca-Cola, UPS, Bank of America...More
- Lilly Reports 7% Sales Growth, 10% Earnings Growth and $.80 EPS for ...
- Lilly Reports 7% Sales Growth, 10% Earnings Growth and $.80 EPS ...
- Amylin Narrows Losses
- Amylin Pharmaceuticals Reports Third Quarter Financial Results
- More Byetta MSN Newsfeeds...
- Nurse.com - On the Cutting Edge of Diabetes Care
- Bloomberg.com: Exclusive
- Biogen Start-up Escoublac Finds Link Between Bones and Obesity
- Ahead of the Bell: Amylin upgraded - Forbes.com
- Insulin Seen Faster In 'Normalizing' Blood Sugar Levels, Shows Study | AHN | June 3, 2008
- UPDATE 2-Novo files for U.S., European liraglutide approval | Reuters
- 2nd UPDATE: Roche Potential Diabetes Drug Gets Strong Rating
- Valuing One-Drug Wonders
- Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
- Gardener lost decade to diabetes - icWales
- Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
- Gardener lost decade to diabetes - icWales
- Diabetes Drugs Could Sweeten Shares - Barrons.com
- Daytrading, Eminis, Forex trading, Swing Trading STOCK ALERT - 567462
- => Nachrichten | BYETTA(R) Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
- A 'Byetta' Alternative to Insulin for Diabetics
- Study - BYETTA better than insulin glargine in treating type 2 diabetes - The Money Times
- BYETTA(R) Study Showed Sustained Blood Glucose Control Over Three Years in People with Type 2 Diabetes
- Amylin, Lilly: Byetta Cuts Hypoglycemia Risk - News & Analysis - Pharmaceuticals - AMLN - LLY
- Pharma Blog Watch
- What Diabetes Patients Need to Know - WSJ.com
- United Press International - Health Business - Analysis
- Amylin Pharmaceuticals "hold" | newratings.com
- SonicWALL "hold" | newratings.com
- Bristol could take advantage ofdiabetes industryturmoil - Jun. 14, 2007
- Bristol could take advantage ofdiabetes industryturmoil - Jun. 14, 2007
- ScienceDaily: Analysis: Sanofi loss upsets obesity field
- Avandia concerns spark regulatory debate | Chron.com - Houston Chronicle
- Avandia Concerns Spark Regulatory Debate - Forbes.com
- Waxman accuses FDA of 'major failure' over Avandia safety - Jun. 6, 2007
- Diabetes drugs to get new warnings
- Avandia Concerns Spark Regulatory Debate, Democrats In Congress Use Avandia Controversy To Push For Tougher Restrictions On Drug Makers - CBS News
- ABC News: Avandia Concerns Spark Regulatory Debate
- Welcome to AJC! | ajc.com
- Glaxo defends Avandia ahead of hearing - Breaking News - Business - Breaking News
- Risks of Glaxo diabetes drug still unclear: FDA| Science & Health| Reuters
- Risks of Glaxo diabetes drug still unclear: FDA
- Risks of Glaxo diabetes drug still unclear: FDA: Scientific American
- F.D.A. Issues Strictest Warning on Diabetes Drugs - New York Times
- Diabetes group urges patient caution on Avandia | Reuters.com
- Avandia to carry stronger warning label
- Avandia to Carry Stronger Warning Label - Forbes.com
- Avandia to Carry Stronger Warning Label | Chron.com - Houston Chronicle
- Avandia to carry stronger warning label - NewsFlash - mlive.com
- The New York Times > Log In
- UPDATE: FDA Wants Black Box On Avandia, Actos Diabetes Drugs
- 3rd UPDATE: FDA Wants Black Box On Avandia, Actos Drugs
- On Avandia, a Niche Strategy Now Under Stress - New York Times
- FDA puts most serious warnings on 2 diabetes drugs | Chron.com - Houston Chronicle
- FDA wants 'black box' warning on Glaxo drug - Triangle Business Journal:
- Sign Up
- FDA seeks warnings on 2 drugs - Newsday.com
- Diabetes drugs to get 'black box' warning - Diabetes - MSNBC.com
- Sign Up
- Top scientist feared $5b Glaxo suit - 08 Jun 2007 - Pharmaceuticals news - NZ Herald
- IndianExpress.com :: US seeks stronger warning for diabetes drugs
- ABC News: House panel to consider FDA bill on drug safety
- Amgen to Buy Company with Diabetes Drug | Health & Drugs | Reuters.co.uk
- UPDATE 1-Amgen to buy company with diabetes drug | Bonds News | Reuters.com
- FDA Wants Black Box Warning on Glaxo's Avandia and Lilly's Actos - Seeking Alpha
- Spending on Diabetes Drugs Soars in US
- Amylin Pharmaceuticals to Present at Banc of America Healthcare Conference
- The monster that can help to lick diabetes-Life & Style-Health-Our Experts-TimesOnline
- Log in: HeraldTimesOnline.com
- United Press International - NewsTrack - Science - Diabetes drug comes from poison lizard
- The Scotsman - International - Threatened lizard's saliva brings boost to diabetics
- PharmaLive: New Report: Unmanaged, Diabetes Drug Costs Could Surge Nearly 70 Percent Within Three Years
- Diabetes Drug Spending Set to Soar by '09
- Diabetes Drug Spending May Surge 70% by 2010, Cancer Now Drives Specialty Drugs
- Prescription Drug Use Up in Teen Girls
- Study: Diabetes Drug Use Spikes in Girls - Forbes.com
- Study: Diabetes Drug Use Spikes in Girls
- Diabetes Drug Costs Could Soar 70 Pct by '09-Report | Health & Drugs | Reuters.co.uk
- Kids' Rx drug use rises - Newsday.com
- Diabetes, Cancer Drugs Drive Costs - Forbes.com
- PharmaLive: Momenta Pharmaceuticals Announces Date for 2007 Annual Meeting of Stockholders
- News: Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders. Genetic Engineering News - Biotechnology from Bench to Business
- San Diego Business Journal Online - San Diego California business news"
- Archives: Story
- MEREDITH CUMMINGS: Diabetics must find balance | TideSports.com
- Eli Lilly rolls out diabetes drug Byetta in Europe| Health| Reuters
- New Type 2 Drugs Januvia and Byetta Offer Big Benefits - Diabetes Health
- Star-Telegram.com | 05/06/2007 | New weapons against diabetes
- Amylin Pharmaceuticals Reports First Quarter Financial Results
- New injectable treatment for type II diabetes - Healthcare Republic News
- U.S. Wonders if Drug Data Was Accurate - New York Times
- Eli Lilly's problems go beyond quarterly results - BloggingStocks
- Eli Lilly rolls out diabetes drug Byetta in Europe| Health| Reuters
- Byetta: Let’s Talk campaign - Diabetes Health
- Delta Burke Hits the Road For Byetta - Diabetes Health
- San Diego Source > News >
- Amylin drops on Byetta competition
- Amylin Drops on Byetta Competition - Forbes.com
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 532850
- Daytrading, Eminis, Forex trading, Swing Trading IMPORTANT WS EVENT - 532931
- Amylin reports smaller loss, higher drug sales | Markets News | Reuters.com
- Amylin reports smaller loss, higher drug sales| News| Market News| Reuters
- Eli Lilly Earnings - News - MSNBC.com
- Therapeutics Daily
- Earnings Preview: Eli Lilly
- More Byetta News Articles...
- Byetta approved as first in new class of medications to treat type 2 diabetes.(News) : An article from: Family Practice News
- From the pharmacy.(MEDICAL MAILBOX): An article from: Saturday Evening Post
- Byetta, Elestrin.(New & Approved)(Drug overview): An article from: Family Practice News
- New diabetes drugs add to Tx Complexity.(Metabolic Disorders) : An article from: Family Practice News
- Losing Weight with Your Diabetes Medication: How Byetta and Other Drugs Can Help You Lose More Weight than You Ever Thought Possible (Marlowe Diabetes Library)
- Amylin posts strong 1Q sales; but biotech must find new suppliers for drug.(Byetta, injection to treat diabetes) : An article from: San Diego Business Journal
- Byetta.(New & Approved): An article from: Skin & Allergy News
- Amylin looks forward to diabetes conference: company plans to promote two of its drugs, Byetta and Symlin.: An article from: San Diego Business Journal
- Byetta approved as first in new class of medications to treat type 2 diabetes.(News): An article from: Family Practice News
- FDA warns of pancreatitis risk with Byetta.(News): An article from: Family Practice News
- First incretin mimetic, Byetta, approved for diabetes: exenatide is formulated for self-administered subcutaneous injection within 1 hour of meals.: An article from: Internal Medicine News






